Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2023 Sep 26;2419:. doi: 10.3390/ijms241914590.
Show Gene links
Show Anatomy links
Synthesis and Biological Activity of a New Indenoisoquinoline Copper Derivative as a Topoisomerase I Inhibitor.
Molinaro C
,
Wambang N
,
Pellegrini S
,
Henry N
,
Lensink MF
,
Germain E
,
Bousquet T
,
de Ruyck J
,
Cailliau K
,
Pélinski L
,
Martoriati A
.
???displayArticle.abstract???
Topoisomerases are interesting targets in cancer chemotherapy. Here, we describe the design and synthesis of a novel copper(II) indenoisoquinoline complex, WN198. The new organometallic compound exhibits a cytotoxic effect on five adenocarcinoma cell lines (MCF-7, MDA-MB-231, HeLa, HT-29, and DU-145) with the lowest IC50 (0.37 ± 0.04 μM) for the triple-negative MDA-MB-231 breast cancer cell line. Below 5 µM, WN198 was ineffective on non-tumorigenic epithelial breast MCF-10A cells and Xenopus oocyte G2/M transition or embryonic development. Moreover, cancer cell lines showed autophagy markers including Beclin-1 accumulation and LC3-II formation. The DNA interaction of this new compound was evaluated and the dose-dependent topoisomerase I activity starting at 1 μM was confirmed using in vitro tests and has intercalation properties into DNA shown by melting curves and fluorescence measurements. Molecular modeling showed that the main interaction occurs with the aromatic ring but copper stabilizes the molecule before binding and so can putatively increase the potency as well. In this way, copper-derived indenoisoquinoline topoisomerase I inhibitor WN198 is a promising antitumorigenic agent for the development of future DNA-damaging treatments.
Figure 1. Biologically active indenoisoquinolines.
Figure 2. Synthesis of the ligand WN191 and the Cu(II) complex WN198.
Figure 3. Molecular structure of Cu complex WN198 showing the local geometry around the copper and ligand. Selected bond lengths (Ǻ) and angles (°): Cu-N1BA 1.998(8); Cu-N4A 2.014(6); Cu-N1AA 1.990(7); Cu-O1W 1.980(7); Cu-O1D 2.333(7); N1BA Cu N4A 85.1(3); N1AA Cu N4A 86.2(3); O1W Cu N1AA 94.5(3); O1W Cu N1BA 94.6(3); N1BA Cu O1D 91.2(4); N4A Cu O1D 101.9(3); N1AA Cu O1D 88.1(3); O1W Cu O1D 94.0(3).
Figure 4. Non-cancerous cell viability under WN198 treatment. (A) MCF-10A IC50 values are expressed as the mean ± SD of three independent experiments. Cisplatin and WN197 were used as control. (B) Xenopus oocyte G2/M transition was scored by the determination of a white spot at the animal pole showing the progression from prophase I to metaphase II (meiosis maturation) 12 h after microinjection and balneation with corresponding drugs (0.5, 1, 5 µM) and external stimulation by progesterone as a natural inducer (4 µM). Experiments were performed on 10 to 20 oocytes from three different females. (C) The viability of Xenopus embryos was followed after incubation with corresponding drugs (0.5, 1, 5 µM). Stages were identified using the Nieuwkoop and Faber table [24]: segmentation, (3 h 30 min after fertilization), gastrulation (9 h after fertilization), neurulation (19 h 45 min after fertilization), tailbud (24 h after fertilization). Experiments were performed on two independent fertilizations and 10 to 40 embryos in each condition.
Figure 5. WN191 and WN198 inhibited human topoisomerase I activity in a dose-dependent manner. Topoisomerase I (Top1) activity is determined by in vitro assays after the addition of either (A) WN198 or (B) WN191 at different concentrations (0.2, 0.5, 1, and 2 µM, lanes 5–8). Relaxed DNA (RDNA, lane 1) or supercoiled DNA (SCDNA, lane 2) is used as migration control. The Top1 activity control allowing the relaxation of SCDNA is in lane 3. DMSO is the solvent control (5%, lane 4). SCDNA is used in all other reactions in the presence of Top1. (C) Etoposide (VP-16, 50 µM; topoisomerase II (Top2) poison, lane 1) is the negative control of Top1 activity inhibition, and camptothecin (CPT, 10 µM; Top1 poison, lane 2) the positive control of Top1 activity inhibition. After topoisomerase reactions, DNA is run in a 1% agarose gel, stained with ethidium bromide (0.5 µg/mL), and visualized under UV light.
Figure 6. Interaction models of the studied ligands and Top1. (A) Crystal structure of the topotecan poison (grey sticks) fitting the DNA groove (orange sticks) of Top1 (brown helices) (PDB ID: 1K4T, 2.1 Å). (B) The binding mode of WN170 (salmon sticks) is similar to topotecan’s binding mode. The main interaction is taking place inside the DNA groove. (C) The interaction model of WN191 (yellow sticks) is slightly different from WN170 as the larger branched arm has to switch down. The main part of the infarction is occurring through the aromatic ring. (D) The binding mode of WN198 (pink sticks with the copper molecule as a blue ball) is similar to the binding mode of WN191.
Figure 7. WN198-induced autophagy. MDA-MB-231, HeLa, and HT-29 cell lines were treated for 24 h with doxorubicin (Dox, 5 µM), rapamycin (Rap, 0.5 µM), or WN198 (0.5, 1, 5 µM). (A) Western blots were performed with anticleaved caspase 3 and anticleaved PARP antibodies for detection of apoptosis. Anti-γH2AX antibody was used for detection of DNA breaks. (B) Western blot analysis of Beclin-1, and LC3 markers were used for detection of autophagy. LC3-II/LC3-I ratio was determined (arrow). β-actin level was used as a loading control. Relative protein levels were expressed by densitometry using software (Fiji Software, v1.52i).
Ali,
Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
2016, Pubmed
Ali,
Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
2016,
Pubmed
Anthony,
Metallodrugs are unique: opportunities and challenges of discovery and development.
2020,
Pubmed
Atwal,
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
2019,
Pubmed
Bailly,
Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
1999,
Pubmed
Baldari,
Current Biomedical Use of Copper Chelation Therapy.
2020,
Pubmed
Barrett-Lee,
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
2009,
Pubmed
Beck,
Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).
2014,
Pubmed
Brown,
Cisplatin-Based Chemotherapy of Human Cancers.
2019,
Pubmed
Ceramella,
From coins to cancer therapy: Gold, silver and copper complexes targeting human topoisomerases.
2020,
Pubmed
Cushman,
Design and Synthesis of Indenoisoquinolines Targeting Topoisomerase I and Other Biological Macromolecules for Cancer Chemotherapy.
2021,
Pubmed
Deng,
π-π stacking interactions: Non-negligible forces for stabilizing porous supramolecular frameworks.
2020,
Pubmed
Denoyer,
Copper Complexes in Cancer Therapy.
2018,
Pubmed
Dilruba,
Platinum-based drugs: past, present and future.
2016,
Pubmed
Grossman,
Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.
2023,
Pubmed
Gul,
New copper complexes inducing bimodal death through apoptosis and autophagy in A549 cancer cells.
2020,
Pubmed
Heestand,
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
2017,
Pubmed
Jaouen,
Ferrocifen type anti cancer drugs.
2015,
Pubmed
Jones,
Development and validation of a genetic algorithm for flexible docking.
1997,
Pubmed
Kim,
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.
2006,
Pubmed
Komeda,
Next-generation anticancer metallodrugs.
2012,
Pubmed
Kondratskyi,
Ferroquine, the next generation antimalarial drug, has antitumor activity.
2017,
Pubmed
Larsen,
From DNA damage to G2 arrest: the many roles of topoisomerase II.
2003,
Pubmed
Lee,
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
2015,
Pubmed
Liang,
A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.
2019,
Pubmed
Marchand,
Effects of Ferrocenyl 4-(Imino)-1,4-Dihydro-quinolines on Xenopus laevis Prophase I - Arrested Oocytes: Survival and Hormonal-Induced M-Phase Entry.
2020,
Pubmed
,
Xenbase
Marinello,
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.
2018,
Pubmed
Marzano,
Copper complexes as anticancer agents.
2009,
Pubmed
Marzi,
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
2020,
Pubmed
McGowan,
Anthracycline Chemotherapy and Cardiotoxicity.
2017,
Pubmed
Meneau,
Translational Control of Xenopus Oocyte Meiosis: Toward the Genomic Era.
2020,
Pubmed
,
Xenbase
Molinaro,
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.
2020,
Pubmed
Molinaro,
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.
2021,
Pubmed
Molinaro,
A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas.
2022,
Pubmed
Ndagi,
Metal complexes in cancer therapy - an update from drug design perspective.
2017,
Pubmed
Park,
Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells.
2011,
Pubmed
Pommier,
Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins.
2018,
Pubmed
Pommier,
Interfacial inhibitors.
2015,
Pubmed
Pommier,
Drugging topoisomerases: lessons and challenges.
2013,
Pubmed
Rezaei,
Effect of a Copper (II) Complex on The Induction of Apoptosis in Human Hepatocellular Carcinoma Cells.
2018,
Pubmed
Rosenberg,
Platinum compounds: a new class of potent antitumour agents.
1969,
Pubmed
Santini,
Advances in copper complexes as anticancer agents.
2014,
Pubmed
Sharma,
Histone H2AX phosphorylation: a marker for DNA damage.
2012,
Pubmed
Shobha Devi,
Recent Advances in Copper Intercalators as Anticancer Agents.
2018,
Pubmed
Slaby,
Maturation of Xenopus laevis oocytes under cadmium and lead exposures: Cell biology investigations.
2017,
Pubmed
,
Xenbase
Slaby,
Cadmium but not lead exposure affects Xenopus laevis fertilization and embryo cleavage.
2016,
Pubmed
,
Xenbase
Slaby,
Exposures to chemical contaminants: What can we learn from reproduction and development endpoints in the amphibian toxicology literature?
2019,
Pubmed
,
Xenbase
Smith,
DNA damage checkpoint kinases in cancer.
2020,
Pubmed
Szczepaniak,
Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review.
2019,
Pubmed
Thomas,
Targeting Topoisomerase I in the Era of Precision Medicine.
2019,
Pubmed
Topatana,
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
2020,
Pubmed
Villman,
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
2002,
Pubmed
Wambang,
Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
2016,
Pubmed
Zhang,
Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
2017,
Pubmed
Zhong,
Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
2020,
Pubmed